小儿葡萄膜炎：新的和未来的治疗方法。
Pediatric uveitis: new and future treatments.
机构信息
National Eye Institute/National Institutes of Health, Bethesda, Maryland 20892, USA.
出版信息
Curr Opin Ophthalmol. 2013 Sep;24(5):453-62. doi: 10.1097/ICU.0b013e3283641ede.
Abstract
PURPOSE OF REVIEW
Pediatric uveitis is relatively uncommon, accounting for only 5-10% of all patients with uveitis. However, owing to high prevalence of complications and devastating outcomes, its lifetime burden can be significant.
RECENT FINDINGS
Immunomodulatory therapy has been associated with better outcomes in noninfectious pediatric uveitis. However, effective treatments are limited by medication-related complications, including multiorgan toxicities and systemic side effects.
SUMMARY
We review the current therapies available to treat pediatric uveitis, discuss novel and future therapies, and provide clinical recommendations utilizing these new agents. The consideration for treatment regimens in noninfectious pediatric uveitis is multifactorial. Understanding past, present, and future technology will aid in treatment of a complex and refractory disease.
摘要
目的综述
小儿葡萄膜炎相对少见，仅占所有葡萄膜炎患者的 5-10%。然而，由于其并发症发生率高，后果严重，其终身负担可能很大。
最新发现
免疫调节疗法与非感染性小儿葡萄膜炎的更好结果相关。然而，有效的治疗方法受到与药物相关的并发症的限制，包括多器官毒性和全身副作用。
总结
我们回顾了目前可用于治疗小儿葡萄膜炎的疗法，讨论了新的和未来的疗法，并利用这些新药物提供了临床建议。非感染性小儿葡萄膜炎的治疗方案考虑因素是多方面的。了解过去、现在和未来的技术将有助于治疗这种复杂和难治性疾病。
相似文献
1
Pediatric uveitis: new and future treatments.
Curr Opin Ophthalmol. 2013 Sep;24(5):453-62. doi: 10.1097/ICU.0b013e3283641ede.
2
Comparison of pediatric patients with noninfectious idiopathic uveitis and noninfectious uveitis associated with an underlying systemic disease: from a referral center in Turkey.
Postgrad Med. 2021 May;133(4):444-448. doi: 10.1080/00325481.2021.1902684. Epub 2021 Mar 31.
3
Therapeutic advances in juvenile idiopathic arthritis - associated uveitis.
Curr Opin Ophthalmol. 2019 May;30(3):179-186. doi: 10.1097/ICU.0000000000000559.
4
[Research progress of medication treatment of pediatric noninfectious uveitis].
Zhonghua Yan Ke Za Zhi. 2023 Mar 11;59(3):231-236. doi: 10.3760/cma.j.cn112142-20220703-00324.
5
Management of chronic pediatric uveitis.
Curr Opin Ophthalmol. 2005 Oct;16(5):281-8. doi: 10.1097/01.icu.0000177414.79030.32.
6
Use of immunosuppressive agents in uveitis.
Curr Opin Ophthalmol. 2003 Dec;14(6):399-412. doi: 10.1097/00055735-200312000-00014.
7
The use of biologic agents in the management of uveitis.
Intern Med J. 2019 Nov;49(11):1352-1363. doi: 10.1111/imj.14215.
8
Pediatric Uveitis in a Well-Defined Population: Improved Outcomes with Immunosuppressive Therapy.
Ocul Immunol Inflamm. 2018;26(6):978-985. doi: 10.1080/09273948.2017.1305420. Epub 2017 Apr 27.
9
[The prospects of the biotherapy for refractory uveitis].
Zhonghua Yan Ke Za Zhi. 2016 Jul;52(7):551-6. doi: 10.3760/cma.j.issn.0412-4081.2016.07.018.
10
Incidence and Prevalence of Pediatric Noninfectious Uveitis in Korea: A Population-Based Study.
J Korean Med Sci. 2022 Dec 19;37(49):e344. doi: 10.3346/jkms.2022.37.e344.
引用本文的文献
1
The Efficacy of Adalimumab Treatment in Pediatric Non-Infectious Uveitis: A Retrospective Cohort Study.
Turk J Ophthalmol. 2024 Dec 31;54(6):337-343. doi: 10.4274/tjo.galenos.2024.70371.
2
Experiences of burden and needs in caregivers with pediatric noninfectious uveitis: a qualitative study.
BMC Nurs. 2024 Dec 19;23(1):929. doi: 10.1186/s12912-024-02602-8.
3
Incidence and Prevalence of Pediatric Noninfectious Uveitis in Korea: A Population-Based Study.
J Korean Med Sci. 2022 Dec 19;37(49):e344. doi: 10.3346/jkms.2022.37.e344.
4
Myopia and Other Visual Disorders in Children.
Int J Environ Res Public Health. 2022 Jul 22;19(15):8912. doi: 10.3390/ijerph19158912.
5
Update on biologic therapies for juvenile idiopathic arthritis-associated uveitis.
Ann Eye Sci. 2021 Jun;6. doi: 10.21037/aes-2019-dmu-10. Epub 2021 Jun 15.
6
Update on the management of uveitis in children: an overview for the clinician.
Expert Rev Ophthalmol. 2019;14(4-5):211-218. doi: 10.1080/17469899.2019.1663731. Epub 2019 Sep 19.
7
Patterns of uveitis in children according to age: comparison of visual outcomes and complications in a tertiary center.
BMC Ophthalmol. 2019 Jun 27;19(1):137. doi: 10.1186/s12886-019-1139-5.
8
A child with tubulointerstitial nephritis and uveitis (TINU) syndrome.
BMJ Case Rep. 2018 Feb 17;2018:bcr-2017-222766. doi: 10.1136/bcr-2017-222766.
9
An Update on Treatment of Pediatric Chronic Non-Infectious Uveitis.
Curr Treatm Opt Rheumatol. 2017 Mar;3(1):1-16. doi: 10.1007/s40674-017-0057-z. Epub 2017 Jan 29.
10
The common NOD2/CARD15 variant P268S in patients with non-infectious uveitis: a cohort study.
Pediatr Rheumatol Online J. 2015 Oct 6;13(1):38. doi: 10.1186/s12969-015-0037-5.
本文引用的文献
1
Biotherapies in inflammatory ocular disorders: Interferons, immunoglobulins, monoclonal antibodies.
Autoimmun Rev. 2013 May;12(7):774-83. doi: 10.1016/j.autrev.2013.02.002. Epub 2013 Mar 5.
2
Adalimumab for juvenile idiopathic arthritis-associated uveitis.
Graefes Arch Clin Exp Ophthalmol. 2013 Jun;251(6):1601-6. doi: 10.1007/s00417-013-2275-x. Epub 2013 Mar 1.
3
Update on the principles and novel local and systemic therapies for the treatment of non-infectious uveitis.
Inflamm Allergy Drug Targets. 2013 Feb;12(1):38-45. doi: 10.2174/1871528111312010006.
4
Infectious causes of posterior uveitis.
Can J Ophthalmol. 2013 Feb;48(1):31-9. doi: 10.1016/j.jcjo.2012.11.013.
5
Pharmacokinetics and safety of sirukumab following a single subcutaneous administration to healthy Japanese and Caucasian subjects.
Int J Clin Pharmacol Ther. 2013 Mar;51(3):187-99. doi: 10.5414/CP201785.
6
A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis.
J Ocul Pharmacol Ther. 2013 Jun;29(5):501-7. doi: 10.1089/jop.2012.0180. Epub 2013 Jan 8.
7
Update on biologicals for treatment of juvenile idiopathic arthritis.
Expert Opin Biol Ther. 2013 Mar;13(3):361-76. doi: 10.1517/14712598.2013.735657. Epub 2013 Jan 5.
8
Behçet disease-associated uveitis successfully treated with golimumab.
Ocul Immunol Inflamm. 2013 Apr;21(2):160-2. doi: 10.3109/09273948.2012.741744. Epub 2012 Dec 19.
9
Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis.
Arthritis Rheum. 2013 Feb;65(2):513-8. doi: 10.1002/art.37776.
10
Dexamethasone implant in pediatric uveitis.
Ophthalmology. 2012 Nov;119(11):2412-2412.e2. doi: 10.1016/j.ophtha.2012.07.025.
Zotero 插件